InvestorsHub Logo
Followers 30
Posts 4136
Boards Moderated 0
Alias Born 07/25/2007

Re: ASPRV post# 2622

Friday, 08/11/2023 3:23:50 AM

Friday, August 11, 2023 3:23:50 AM

Post# of 3013

But the guidance is still less than last year, like 1 of 3.



So what? Paxlovid sold $18.1 billion in 2022 and $4.1 billion in Q1 of 2023. That isn't peanuts.

https://www.fiercepharma.com/pharma/pfizer-pulls-q1-surprise-sales-covid-products-despite-plummeting-demand

https://www.fiercepharma.com/pharma/pfizer-sees-covid-19-vaccine-sales-falling-64-2023-paxlovid-declining-58

Do you think the transition to traditional commercial markets is better for Paxlovid's revenue? Care to elaborate?



What in the world are you talking about?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News